Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EBITDA (2023 - 2025)

Immunome (IMNM) has disclosed EBITDA for 3 consecutive years, with -$72.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 12.18% year-over-year to -$72.9 million, compared with a TTM value of -$224.1 million through Dec 2025, up 26.71%, and an annual FY2025 reading of -$224.1 million, up 26.71% over the prior year.
  • EBITDA was -$72.9 million for Q4 2025 at Immunome, down from -$60.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$4.5 million in Q1 2023 and bottomed at -$132.3 million in Q1 2024.
  • Average EBITDA over 3 years is -$53.3 million, with a median of -$48.5 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 2859.05% in 2024, then skyrocketed 66.26% in 2025.
  • Year by year, EBITDA stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then grew by 12.18% to -$72.9 million in 2025.
  • Business Quant data shows EBITDA for IMNM at -$72.9 million in Q4 2025, -$60.1 million in Q3 2025, and -$46.5 million in Q2 2025.